HBM Holdings’ subsidiary, Nona Biosciences, entered a research collaboration with the Medical University of Vienna to advance fully human antibody development for infectious diseases. The announcement is development-stage and does not provide financial metrics, but it modestly improves pipeline and R&D credibility.
HBM Holdings’ subsidiary, Nona Biosciences, entered a research collaboration with the Medical University of Vienna to advance fully human antibody development for infectious diseases. The announcement is development-stage and does not provide financial metrics, but it modestly improves pipeline and R&D credibility.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
